Trials / Withdrawn
WithdrawnNCT05647512
Study of LM-305 in Patients With Relapsed or Refractory Multiple Myeloma (RRMM) and Other Plasma Cell Diseases
A Phase I/II, Open-Label, Multiple Centre Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity and Preliminary Efficacy of LM-305 in Patients With Relapsed or Refractory Multiple Myeloma (RRMM) and Other Plasma Cell Diseases
- Status
- Withdrawn
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 0 (actual)
- Sponsor
- LaNova Medicines Limited · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
A Phase I/II Study of LM-305 in Patients with Relapsed or Refractory Multiple Myeloma (RRMM)
Detailed description
A Phase I/II, Open-Label, Multiple Centre Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity and Preliminary Efficacy of LM-305 in Patients with Relapsed or Refractory Multiple Myeloma (RRMM)
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | LM-305 | Administered intravenously |
| DRUG | Dexamethasone | Administered orally |
Timeline
- Start date
- 2023-01-18
- Primary completion
- 2024-12-01
- Completion
- 2025-12-30
- First posted
- 2022-12-12
- Last updated
- 2023-11-18
Source: ClinicalTrials.gov record NCT05647512. Inclusion in this directory is not an endorsement.